Business

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“PharmAla” or the “Company”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “Term Sheet”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generati

articleJupiter Neurosciences, Inc.May 20, 2026/company/jupiter-neurosciences-inc-common-stock/news/pharmala-biotech-signs-term-sheet-to-license-exclusive-us-rights-to-ala-002-its-next-generation-mdma-therapeutic-to-jupiter-neurosciences-inc-nasdaq-juns-in-a-transaction-valued-at-over-dollar100-million
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

About this update from Jupiter Neurosciences, Inc.

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“PharmAla” or the “Company”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “Term Sheet”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generati

More updates from Jupiter Neurosciences, Inc.